Multicenter Phase II Study of FOLFOX6 for Previously Untreated Unresectable Metastatic Colorectal Cancer

Journal of Integrative Oncology ◽

10.4172/2329-6771.1000120 ◽

2014 ◽

Vol 03 (02) ◽

Author(s):

Satoru Iwasa

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Multicenter Phase ◽

Unresectable Metastatic Colorectal Cancer

Download Full-text

420P A single-arm, multicenter, phase II study of anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ALTER-C002)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.941 ◽

2021 ◽

Vol 32 ◽

pp. S545

Author(s):

K. Ding ◽

Y. Liu ◽

J. Du ◽

Y. Zhu ◽

D. Xu ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Wild Type ◽

Multicenter Phase ◽

First Line Treatment ◽

Unresectable Metastatic Colorectal Cancer

Download Full-text

Capecitabine in combination with oxaliplatin as first line therapy for patients (pts) with advanced or metastatic colorectal cancer (ACRC): preliminary results of an international multicenter phase II study

European Journal of Cancer ◽

10.1016/s0959-8049(01)81497-0 ◽

2001 ◽

Vol 37 ◽

pp. S272 ◽

Author(s):

C. Twelves ◽

C. Butts ◽

J. Cassidy ◽

Th. Conroy ◽

F. DeBraud ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Preliminary Results ◽

First Line Therapy ◽

Multicenter Phase ◽

Line Therapy ◽

International Multicenter

Download Full-text

BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703)

Annals of Oncology ◽

10.1093/annonc/mdy281.152 ◽

2018 ◽

Vol 29 ◽

pp. viii201-viii202 ◽

Author(s):

D. Kotani ◽

H. Bando ◽

T. Masuishi ◽

Y. Komatsu ◽

K. Yamaguchi ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Braf Inhibitor ◽

Mek Inhibitor ◽

Big Bang ◽

Multicenter Phase ◽

Download Full-text

A multicenter phase II study of irinotecan (CPT) and 5-fluorouracil (5FU)/l-leucovorin (l-LV) in patients with metastatic colorectal cancer: Interim results

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3667 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3667-3667

Author(s):

H. Fujishima ◽

K. Uchino ◽

O. Miyanaga ◽

A. Ueda ◽

K. Miyazaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Multicenter Phase

Download Full-text

Multicenter phase II study of irinotecan plus weekly bolus 5-FU and high dose l-leucovorin for patients with metastatic colorectal cancer (OGSG 0201)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3718 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3718-3718

Author(s):

H. Ishida ◽

H. Mishima ◽

S. Iwamoto ◽

T. Morimoto ◽

T. Kato ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

High Dose ◽

Multicenter Phase ◽

Download Full-text

Multicenter phase II study using increasing dose of irinotecan (CPT11) combined with simplified LV5FU regimen in metastatic colorectal cancer (MCRC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3601 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3601-3601

Author(s):

M. Ychou ◽

S. Gourgou ◽

F. Desseigne ◽

C. Debrigode ◽

L. Mineur ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Multicenter Phase

Download Full-text

A multicenter phase II study of irinotecan (CPT-11) and bolus 5-fluorouracil (5FU)/l-leucovorin (l-LV) in patients with metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3742 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3742-3742

Author(s):

H. Fujishima ◽

A. Makiyama ◽

O. Miyanaga ◽

A. Ueda ◽

T. Esaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Multicenter Phase

Download Full-text

An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3583 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3583-3583 ◽

Author(s):

A. L. A. Fields ◽

D. A. Rinaldi ◽

C. A. Henderson ◽

C. J. Germond ◽

L. Chu ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Second Line ◽

Second Line Therapy ◽

Multicenter Phase ◽

Download Full-text

PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps189 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS189-TPS189

Author(s):

L. S. Schwartzberg ◽

V. J. Wagner

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Unresectable Metastatic Colorectal Cancer

Download Full-text

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

International Journal of Clinical Oncology ◽

10.1007/s10147-015-0943-z ◽

2016 ◽

Vol 21 (4) ◽

pp. 705-712 ◽

Author(s):

Yuji Miyamoto ◽

Akihito Tsuji ◽

Hiroaki Tanioka ◽

Soichiro Maekawa ◽

Hirofumi Kawanaka ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Chemotherapy ◽

Multicenter Phase ◽

Line Chemotherapy

Download Full-text